ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zachary Prensky who wrote (350)	7/31/1997 12:58:00 PM
From: Eduardo Canto	of 572

This is how I see it. In the ph II trial, the results for serious infections which is their primary endpoint for the ph III were 7 infections out of 32 patients in the placebo and lowest dose of Betafectin (previously showed to be inactive) combined. In the two higher doses there was 1 infection out of a similar number of patients. The P value for these numbers was 0.02. This tells me that if the ph III is run the same way as the ph II we have a 98% chance of this working to reduce the rate of serious infections sevenfold. The odds are actually very good. I think we will see some action tomorrow. E.C.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next